Literature DB >> 2993609

Stereostructure-activity relationship of opioid agonist and antagonist bivalent ligands. Evidence for bridging between vicinal opioid receptors.

P S Portoghese, D L Larson, C B Yim, L M Sayre, G Ronsisvalle, A W Lipkowski, A E Takemori, K C Rice, S W Tam.   

Abstract

Mesh：

Substances：

Year:  1985        PMID： 2993609     DOI： 10.1021/jm00147a002

Source DB:  PubMed          Journal:  J Med Chem        ISSN： 0022-2623            Impact factor:   7.446


× No keyword cloud information.
  17 in total

1.  Naloxone can act as an analgesic agent without measurable chronic side effects in mice with a mutant mu-opioid receptor expressed in different sites of pain pathway.

Authors:  Shu-Husan Chou; Jen-Hsin Kao; Pao-Luh Tao; Ping-Yee Law; Horace H Loh
Journal:  Synapse       Date:  2012-03-31       Impact factor: 2.562

2.  Pharmacological properties of bivalent ligands containing butorphan linked to nalbuphine, naltrexone, and naloxone at mu, delta, and kappa opioid receptors.

Authors:  Xuemei Peng; Brian I Knapp; Jean M Bidlack; John L Neumeyer
Journal:  J Med Chem       Date:  2007-04-04       Impact factor: 7.446

3.  Opioid-induced tolerance and dependence in mice is modulated by the distance between pharmacophores in a bivalent ligand series.

Authors:  David J Daniels; Natalie R Lenard; Chris L Etienne; Ping-Yee Law; Sandra C Roerig; Philip S Portoghese
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-19       Impact factor: 11.205

4.  Synthesis and binding affinity of novel mono- and bivalent morphinan ligands for κ, μ, and δ opioid receptors.

Authors:  Bin Zhang; Tangzhi Zhang; Anna W Sromek; Thomas Scrimale; Jean M Bidlack; John L Neumeyer
Journal:  Bioorg Med Chem       Date:  2011-03-26       Impact factor: 3.641

5.  An immunocytochemical-derived correlate for evaluating the bridging of heteromeric mu-delta opioid protomers by bivalent ligands.

Authors:  Ajay S Yekkirala; Alexander E Kalyuzhny; Philip S Portoghese
Journal:  ACS Chem Biol       Date:  2013-05-17       Impact factor: 5.100

6.  In vivo characterization of (-)(-)MCL-144 and (+)(-)MCL-193: isomeric, bivalent ligands with mu/kappa agonist properties.

Authors:  Jennifer L Mathews; Brian S Fulton; S Stevens Negus; John L Neumeyer; Jean M Bidlack
Journal:  Neurochem Res       Date:  2008-06-05       Impact factor: 3.996

7.  A study of the structure-activity relationship of GABA(A)-benzodiazepine receptor bivalent ligands by conformational analysis with low temperature NMR and X-ray analysis.

Authors:  Dongmei Han; F Holger Försterling; Xiaoyan Li; Jeffrey R Deschamps; Damon Parrish; Hui Cao; Sundari Rallapalli; Terry Clayton; Yun Teng; Samarpan Majumder; Subramaniam Sankar; Bryan L Roth; Werner Sieghart; Roman Furtmuller; James K Rowlett; Michael R Weed; James M Cook
Journal:  Bioorg Med Chem       Date:  2008-09-02       Impact factor: 3.641

8.  A bivalent ligand (KMN-21) antagonist for mu/kappa heterodimeric opioid receptors.

Authors:  Shijun Zhang; Ajay Yekkirala; Ye Tang; Philip S Portoghese
Journal:  Bioorg Med Chem Lett       Date:  2009-11-04       Impact factor: 2.823

9.  Bivalent ligands that target μ opioid (MOP) and cannabinoid1 (CB1) receptors are potent analgesics devoid of tolerance.

Authors:  Morgan Le Naour; Eyup Akgün; Ajay Yekkirala; Mary M Lunzer; Mike D Powers; Alexander E Kalyuzhny; Philip S Portoghese
Journal:  J Med Chem       Date:  2013-06-20       Impact factor: 7.446

10.  Induced association of mu opioid (MOP) and type 2 cholecystokinin (CCK2) receptors by novel bivalent ligands.

Authors:  Yaguo Zheng; Eyup Akgün; Kaleeckal G Harikumar; Jessika Hopson; Michael D Powers; Mary M Lunzer; Laurence J Miller; Philip S Portoghese
Journal:  J Med Chem       Date:  2009-01-22       Impact factor: 7.446
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.